Arbutus Biopharma Corporation (NASDAQ:ABUS) finished Wednesday with a subtraction of -$0.11 to close at $2.22, a downside of -4.72 percent. An average of 930,180 shares of common stock have been traded in the last five days. There was a fall of -$0.20 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 1,019,590 shares traded, while the 50-day average volume stands at 980,530.
ABUS stock has decreased by -13.95% in the last month. The company shares reached their 1-month lowest point of $2.20 on 12/28/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $1.85 and a high of $4.03 in 52 weeks. It has reached a new high 1 time so far this year and lost -42.93% or -$1.67 in price. In spite of this, the price is down -44.91% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
Arbutus Biopharma Corporation (ABUS) stock’s beta is 2.11. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 9.73, the price-to-book (PB) ratio at 2.31.
The quick ratio of Arbutus Biopharma Corporation for the three months ended June 29 was 5.10, and the current ratio was 5.10, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $84.51 million compared to revenue of $10.99 million.
For the three-month period that ended June 29, Arbutus Biopharma Corporation had $110.71 million in cash. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$17.57 million in the quarter, while revenues of -$14.19 million were shrunk -38.02%. The analyst consensus anticipated Arbutus Biopharma Corporation’s latest quarter earnings to come in at -$0.13 per share, but it turned out to be -$0.1, a 23.10% surprise. For the quarter, EBITDA amounted to -$17.47 million. Shareholders own equity worth $156.47 million.
From a technical analysis perspective, let’s take a brief look at Arbutus Biopharma Corporation (ABUS) price momentum. RSI 9-day as of the close on 28 December was 26.46%, suggesting the stock is oversold, with historical volatility in this time frame at 53.34%.
As of today, ABUS’s price is $2.35 -8.26% or -$0.20 from its 5-day moving average. ABUS is currently trading -7.11% lower than its 20-day SMA and -12.25% lower than its 100-day SMA. However, the stock’s current price level is +1.37% above the SMA50 and -21.00% below the SMA200.
The stochastic %K and %D were 10.16% and 13.25%, respectively, and the average true range (ATR) was 0.15. With the 14-day stochastic at 3.29% and the average true range at 0.15, the RSI (14) stands at 35.23%. The stock has reached -0.13 on the 9-day MACD Oscillator while the 14-day reading was at -0.22.
Jefferies upgraded Arbutus Biopharma Corporation (NASDAQ: ABUS) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a Hold. The consensus rating for Arbutus Biopharma Corporation (ABUS) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ABUS, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 4 others rate it as a “buy”.
What is ABUS’s price target for the next 12 months?
Analysts predict a range of price targets between $4.00 and $6.00, with a median target of $6.00. Taking a look at these predictions, the average price target given by analysts for Arbutus Biopharma Corporation (ABUS) stock is $5.40.